

Corresponding author(s): Alison E. Ondrus

Last updated by author(s): Apr 19, 2020

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist.

<u> </u>				
C 1	トつ	+ 1	-	ics
^			SI	11 >

FUI	an statistical analyses, commit that the following items are present in the figure legenta, table legenta, main text, or Methods section.
n/a	Confirmed
	$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🗴 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
x	A description of all covariates tested
x	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
×	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
X	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	\mathbf{x} Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

No commercial or open-source code was used to collect data for this study

Data analysis

GraphPad Prism, Bio-Rad Image Lab Software v6.0 (https://www.bio-rad.com/en-us/product/image-lab-software), PROMALS3D (https://www.bio-rad.com/en-us/product prodata.swmed.edu/promals3d/promals3d.php), JPred (http://www.compbio.dundee.ac.uk/jpred/), HELIQUEST (https:// heliquest.ipmc.cnrs.fr/), Robetta (http://new.robetta.org/), MCPep (http://bental.tau.ac.il/MCPep/), ImageJ Coloc2 (https://imagej.net/ Coloc_2). All references are provided in the manuscript.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Field-specific reporting

Life sciences study design

	s study design			
All studies must disclose or	n these points even when the disclosure is negative.			
Sample size All data	points represent the average of three or more biological replicates \pm s.d.			
Data exclusions No data	was excluded from the analysis			
Replication All atte	attempts at replication were successful			
Randomization Random	tion was not applied; internal controls were included in each experiment			
Blinding	was not performed			
We require information from system or method listed is released in the study X	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging			
<u> Antibodies</u>				
Antibodies used	Primary antibodies: Shh Antibody (E-1) (N-terminus), (Santa Cruz Biotechnology, sc-365112), Sonic Hedgehog/Shh C-Terminus Antibody (R&D Systems, AF445), Loading control: Karyopherin β1 (H-7) (Santa Cruz Biotechnology, sc-137016). Secondary antibodies: Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 487 (Invitrogen, A-21447), Donkey anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (Invitrogen, A-21202).			
Validation	All antibodies used were validated for Western Blot applications in images provided by the vendor and peer-reviewed citations			
Eukaryotic cell lin				
Policy information about <u>c</u>				
Cell line source(s)	HEK293T (ATCC, CRL-3216)			
Authentication	Cells were obtained from ATCC and expanded directly from the original vial			
Mycoplasma contamination Cell lines tested negative for mycoplasma contamination, checked monthly with the MycoAlert Mycoplasma D (Lonza, LT07-118)				
Commonly misidentified (See <u>ICLAC</u> register)	lines N/A			